As part of its global strategy, New Zealand medicinal cannabis company Ora Pharm launched in Australia this week. Ora Pharm is the first New Zealand medical cannabis company to export a branded product to an international market. Australia is Ora Pharm’s first export market entry and will build strong revenue streams through the sale of dried flowers and branded finished products.

As Australia witnesses an exponentially exploding demand projected to account for 99 cents per dollar of the $18.6 billion Oceanic industrial hemp market in 2028, Ora Pharm will see rapid growth.

Ora Pharm has developed patient-ready tincture formulations that are manufactured and distributed under strict GMP processes by Canngea, one of Australia’s leading medical cannabis manufacturing and distribution companies. Ora Pharm is also developing unique cannabis strains exclusively for Canngea.

Ora Pharm’s ready-to-patient oral solutions for the Australian and New Zealand markets are distributed through Canngea and ANSPEC, which is one of the largest distributors of medicinal cannabis in Australia and has approximately 4,500 dispensaries in its customer base. Ora Pharm branded products are also listed on Catalyst by honahlee, a medical cannabis education platform and cannabis medicine database for healthcare professionals. Listing products on Catalyst gives healthcare professionals more transparency into product details, consistent with Ora Pharm’s mission of making informed healthcare decisions.

Ora Pharm’s Founder and CEO, Zoe Reece, says this is the start of the execution of an exciting global strategy to provide unique, high-quality, pharmaceutical-grade medical cannabis products to meet fast-growing international and domestic demand. “We achieved everything we set out to do and more with our seed funding. We are now entering an important growth phase where Ora Pharm will expand our operations in New Zealand, launch our first line of products, launch in global markets and begin research and development,” said Zoe Reece, Founder and CEO of Ora Pharm .

In a market with very high regulatory barriers to entry and emerging competitors, Ora Pharm stands out as the only company with significant experience in the medical cannabis market and a strong US market platform to drive growth. Zoe Reece (CEO and Founder) and Stuart Wilcox (Executive Chairman and Head of International Business Development) bring a wealth of experience having previously held senior positions at Curaleaf, one of the largest and most respected cannabis companies in North America.

Ora Pharm is currently conducting a Series A funding round through the Syndex Exchange, an online platform that allows individuals to invest in fractional assets. This is a great opportunity to invest in a leading medical cannabis company in a rapidly growing emerging industry and at an attractive early stage valuation.

END

02/19/2022

Ora Pharm was founded to help people make informed health decisions and improve their quality of life. We are a health and wellness company developing pharmaceutical grade medicinal cannabis in the heart of New Zealand.

Our vision is to provide quality plant-based health products to patients, caregivers and physicians that support daily well-being and improve the quality of life.

Ora Pharm is ideally positioned to become New Zealand’s leading supplier of high-quality, pharmaceutical-grade medicinal cannabis products to meet fast-growing international and domestic demand.

In a market with very high regulatory barriers to entry and emerging competitors, Ora Pharm stands out as the only company with significant experience in the medical cannabis market and a strong US market platform to drive growth. Zoe Reece (CEO and Founder) and Stuart Wilcox (Executive Chairman and Head of International Business Development) bring a wealth of experience having previously held senior positions at Curaleaf, one of the largest and most respected cannabis companies in North America.

Ora Pharm recently launched a free app designed to help patients use medicinal cannabis safely and effectively and develop healthy habits to support overall well-being. The app creates a direct connection between patients and doctors via a secure portal. Patients can share timely information about their medications, symptoms, and lifestyle, helping physicians adjust dosages of new and existing medications and provide tailored care and support via in-app messaging. The recently launched research arm will even allow participants in phase one to three clinical trials to provide real-time, anonymized data via their OraPharm app on their smartphone.

© Scoop Media

Support the news you love

Scoop has been an advocate of independent journalism and open publishing for over 20 years. It stands for informing New Zealanders through honest, independent journalism, publishing news across politics and a variety of sectors. Now more than ever, sustained financial support will help keep these important and participatory media services running.

Find out more and get involved:

Join Get our free Pānui